Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Exercise therapy aims to boost recovery in Bone-Weakened myeloma patients

NCT ID NCT07388147

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether orthopedic check-ups and custom exercise plans can improve physical function and rehabilitation in people with multiple myeloma who have bone lesions. About 71 newly diagnosed patients will receive ongoing bone stability assessments and tailored exercise advice during their cancer treatment. The goal is to create a safe, routine program that helps patients stay active and recover better.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
exercise therapy
What this could lead to
If successful, this could provide a safe, structured exercise program to help multiple myeloma patients improve physical function and quality of life during treatment.
What could go wrong
This is a small, early-stage study (71 participants) focused on feasibility, not a large trial. Results may not apply to all patients, and exercise risks for those with bone lesions need careful monitoring.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 71 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Mar 2026

An estimate. Start dates often move.

Expected to finish

Mar 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * newly diagnosed multiple myeloma * Survival prognosis \> 6 months * ECOG status ≤ 3 * Age ≥18 years * Patients who state that they want to carry out the training program at least 2 x/week and participate in the planned follow-up visits * Ability to give informed consent * Written consent to participate in the study * Sufficient knowledge of written and spoken German Exclusion Criteria: * physical or mental limitation that would prevent participation in the training program or the planned follow-up visits

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple myeloma bone lesions are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Heidelberg University Hospital - GMMG Study Group

    Heidelberg, 69120, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.